SARS-CoV-2 Infection Linked to Incidence of BPH Complications
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Oct. 20, 2023 -- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with an increased incidence of benign prostatic hyperplasia (BPH) complications, including urine retention and hematuria, according to a study published online Oct. 18 in the Journal of Internal Medicine.
Alex Qinyang Liu, M.D., from The Chinese University of Hong Kong, and colleagues examined the correlation between SARS-CoV-2 infection and BPH complications using large-scale real-world data. Data were included for male patients attending the public health care system in Hong Kong receiving alpha-blocker monotherapy for lower urinary tract symptoms from 2021 to 2022; patients with and without a positive polymerase chain reaction test for SARS-CoV-2 were selected as the exposure and control groups, respectively.
The analysis included 17,986 patients after propensity score matching, of whom half (8,993) had confirmed SARS-CoV-2 infection. The researchers found that the SARS-CoV-2 group had a significantly higher incidence of retention of urine, hematuria, clinical urinary tract infection, culture proven bacteriuria, and addition of a 5-alpha reductase inhibitor (5ARI) compared with controls. Across different age groups, similar differences were seen in subgroup analyses. No significant differences in the incidence of retention, hematuria, or addition of a 5ARI were seen across different COVID-19 severities.
"We are excited to be the first to report the effects of COVID-19 on complications of benign prostatic hyperplasia -- or enlarged prostate -- and also demonstrate the alarming extent of its urological effects," Liu said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Further Support and Information on COVID-19
Read this next
Aquablation, HoLEP Provide Unique Benefits for Men With Benign Prostate Hyperplasia
TUESDAY, June 4, 2024 -- For men with benign prostate hyperplasia, aquablation provides temporary benefits for ejaculation and continence at three months, while holmium laser...
No Decline in Cardiovascular Events Seen With COVID-19 Vaccine After Acute Coronary Syndromes
MONDAY, June 3, 2024 -- Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events...
Mortality Higher for COVID-19 Hospitalization Than for Flu in 2023/2024 Season
WEDNESDAY, May 22, 2024 -- In fall/winter 2023/2024, the risk for death in patients hospitalized for COVID-19 was greater than the risk for death in patients hospitalized for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.